Clopidogrel, cilostazol — Competitive Intelligence Brief

Clopidogrel, cilostazol (Clopidogrel, cilostazol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination. Area: Cardiovascular.

marketed Antiplatelet agent combination P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol) Cardiovascular Small molecule

Target snapshot

Clopidogrel, cilostazol (Clopidogrel, cilostazol) — Kyunghee University Medical Center. This combination of clopidogrel and cilostazol works by inhibiting platelet aggregation through different pathways to reduce thrombotic events.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel, cilostazol TARGET	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
Ticagrelor plus aspirin	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
Dabigatran + clopidogrel	Dabigatran + clopidogrel	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
Edoxaban plus Single Antiplatelet Agent	Edoxaban plus Single Antiplatelet Agent	Gi-Byoung Nam	marketed	Factor Xa inhibitor + antiplatelet agent combination	Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent)
Dual antiplatelet agent duration	Dual antiplatelet agent duration	Seoul National University Hospital	marketed	Antiplatelet agent combination	Cyclooxygenase (COX) and P2Y12 receptor
Dabigatran + Ticagrelor	Dabigatran + Ticagrelor	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination class)

1. Beijing Tiantan Hospital · 1 drug in this class
2. Biosensors Europe SA · 1 drug in this class
3. Inova Health Care Services · 1 drug in this class
4. Kyunghee University Medical Center · 1 drug in this class
5. Seoul National University Hospital · 1 drug in this class
6. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
7. University Hospital, Bordeaux · 1 drug in this class